Giuseppe Viscardi

Hello, #MedSky community! We’re excited to begin our Bluesky journey.

Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:

Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial Perioperative chemoimmunotherapy showed a promising long-term benefit with no concerning safety data, reinforcing its use in resectable stage IIIA NSCLC.

69% five-years survival rate with perioperative chemo-immunotp in resectable stage III NSCLC: NADIM trial establishes a new milestone
www.thelancet.com/journals/lan...